Dr Othman Al-Sawaf speaks to ecancer about results from the CLL17 trial presented at ASH 2025 comparing continuous and fixed-duration targeted therapies in previously untreated chronic lymphocytic leukaemia (CLL).

The study shows that fixed-duration regimens with venetoclax plus obinutuzumab or venetoclax plus ibrutinib are non-inferior to continuous ibrutinib in terms of progression-free survival at three years.

Dr Al-Sawaf explains that fixed-duration treatment achieved higher complete response and undetectable minimal residual disease rates, while overall survival remained comparable across all arms.

He reports that these findings provide the first direct phase 3 comparison of the two major treatment paradigms in CLL and support fixed-duration targeted therapy as a preferred frontline option.